AU2001239791A1 - Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production - Google Patents
Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein productionInfo
- Publication number
- AU2001239791A1 AU2001239791A1 AU2001239791A AU3979101A AU2001239791A1 AU 2001239791 A1 AU2001239791 A1 AU 2001239791A1 AU 2001239791 A AU2001239791 A AU 2001239791A AU 3979101 A AU3979101 A AU 3979101A AU 2001239791 A1 AU2001239791 A1 AU 2001239791A1
- Authority
- AU
- Australia
- Prior art keywords
- succinoylamino
- carbocycles
- heterocycles
- inhibitors
- protein production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18318600P | 2000-02-17 | 2000-02-17 | |
US60183186 | 2000-02-17 | ||
PCT/US2001/005236 WO2001060826A2 (en) | 2000-02-17 | 2001-02-16 | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001239791A1 true AU2001239791A1 (en) | 2001-08-27 |
Family
ID=22671796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001239791A Abandoned AU2001239791A1 (en) | 2000-02-17 | 2001-02-16 | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production |
Country Status (6)
Country | Link |
---|---|
US (1) | US6525044B2 (en) |
EP (1) | EP1261610A2 (en) |
JP (1) | JP2003523345A (en) |
AU (1) | AU2001239791A1 (en) |
CA (1) | CA2395862A1 (en) |
WO (1) | WO2001060826A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9917082A (en) | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compounds that inhibit the production of "beta" proteins, a method of treating neurological disorders associated with the production of "beta" -amyloid, pharmaceutical composition and, method of inhibiting y-secretase activity |
EP1261610A2 (en) | 2000-02-17 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production |
BR0110051A (en) | 2000-04-03 | 2004-12-07 | Bristol Myers Squibb Pharma Co | Compound, Compound Use, Pharmaceutical Composition and Method of Treatment of Alzheimer's Disease |
US7146209B2 (en) * | 2000-05-08 | 2006-12-05 | Brainsgate, Ltd. | Stimulation for treating eye pathologies |
WO2001087354A2 (en) | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
AU783857B2 (en) * | 2000-06-01 | 2005-12-15 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of a beta protein production |
US7399775B2 (en) * | 2001-12-27 | 2008-07-15 | Daiichi Pharmaceutical Co., Ltd. | β-amyloid protein production/secretion inhibitor |
US7684859B2 (en) * | 2002-04-25 | 2010-03-23 | Brainsgate Ltd. | Stimulation of the OTIC ganglion for treating medical conditions |
KR20050000409A (en) * | 2002-04-25 | 2005-01-03 | 브레인스게이트 리미티드 | Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head |
WO2004043218A2 (en) * | 2002-11-14 | 2004-05-27 | Brainsgate Ltd. | Surgical tools and techniques for stimulation |
US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
US8010189B2 (en) * | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
WO2006021957A2 (en) * | 2004-08-23 | 2006-03-02 | Brainsgate Ltd. | Concurrent bilateral spg modulation |
CA2635354C (en) * | 2005-12-29 | 2012-07-10 | Immupharma France Sa | Compositions and methods for the inhibition of phospholipase a2 |
EP1973887B1 (en) * | 2005-12-29 | 2012-09-19 | Immupharma France SA | Aza heterocyclics for the treatment of malaria or aids |
US20090210026A1 (en) * | 2006-08-17 | 2009-08-20 | Brainsgate Ltd. | Spg stimulation for enhancing neurogenesis and brain metabolism |
WO2008099210A2 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
CN101284828B (en) * | 2007-04-12 | 2011-04-27 | 中国科学院上海药物研究所 | Cycloheptapyridine compounds, preparation method thereof, use and pharmaceutical compositions containing the compounds |
US7860569B2 (en) | 2007-10-18 | 2010-12-28 | Brainsgate, Ltd. | Long-term SPG stimulation therapy for prevention of vascular dementia |
CN101945853B (en) | 2007-12-21 | 2014-08-20 | 配体药物公司 | Selective androgen receptor modulators (sarms) and uses thereof |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
US20120142672A1 (en) | 2009-07-13 | 2012-06-07 | Tatsuki Koike | Heterocyclic compound and use thereof |
BR112013004746A2 (en) | 2010-09-02 | 2016-06-07 | Takeda Pharmaceutical | "compound, medicament, beta-amyloid production inhibitor, gamma secretase modulator, methods for inhibiting beta-amyloid production, for modulating gamma secretase, and for preventing or treating mild or alzheimer's cognitive impairment, and, use of compost. " |
TWI530489B (en) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
CN104822665A (en) * | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch inhibitors |
WO2014047374A1 (en) * | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
TWI614238B (en) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof |
WO2014047370A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl dibenzodiazepinone compounds |
WO2014047391A1 (en) * | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
JP2015533811A (en) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | N-substituted bis (fluoroalkyl) 1,4-benzodiazepinone compounds |
EP2897954B1 (en) | 2012-09-21 | 2016-10-26 | Bristol-Myers Squibb Company | Fluoroalkyl-1,4-benzodiazepinone compounds |
US9249157B2 (en) | 2012-09-21 | 2016-02-02 | Bristol-Myers Squibb Company | Tricyclic heterocycle compounds |
JP2016515625A (en) | 2013-04-04 | 2016-05-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Combination therapy to treat proliferative diseases |
US9675796B2 (en) | 2013-11-10 | 2017-06-13 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
EP3093043B1 (en) | 2015-05-13 | 2018-11-14 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2630440B1 (en) * | 1988-04-25 | 1991-09-20 | Jouveinal Sa | BENZODIAZEPINES, THEIR PREPARATION PROCESS AND INTERMEDIATES AND THEIR THERAPEUTIC APPLICATIONS |
EP0727215A3 (en) | 1989-08-04 | 1996-11-06 | Merck Sharp & Dohme | Central cholecystokinin antagonists for treatment of psychiatric disorders |
CA2026856A1 (en) | 1989-10-05 | 1991-04-06 | Mark G. Bock | 3-substituted-1,4-benzodiazepines useful as oxytocin |
CA2032427A1 (en) | 1989-12-18 | 1991-06-19 | Mark G. Bock | Benzodiazepines analogs |
GB9107368D0 (en) | 1991-04-08 | 1991-05-22 | Smithkline Beecham Plc | Novel compounds |
ATE207064T1 (en) | 1992-07-29 | 2001-11-15 | Merck Sharp & Dohme | BENZODIAZEPINE DERIVATIVES |
US5283241A (en) | 1992-08-28 | 1994-02-01 | Merck & Co., Inc. | Benzo-fused lactams promote release of growth hormone |
DE69332860T2 (en) | 1992-12-21 | 2004-03-11 | Smithkline Beecham Corp. | BICYCLIC FIBRINOGEN ANTAGONISTE |
MX9308016A (en) | 1992-12-22 | 1994-08-31 | Lilly Co Eli | HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITING COMPOUNDS, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATION CONTAINING THEM. |
JPH09500615A (en) | 1993-05-14 | 1997-01-21 | ジェネンテク,インコーポレイテッド | Ras-farnesyl transferase inhibitor |
JPH08511538A (en) | 1993-06-09 | 1996-12-03 | スミスクライン・ビーチャム・コーポレイション | Bicyclic fibrinogen antagonist |
US5602156A (en) * | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
US5545735A (en) | 1993-10-04 | 1996-08-13 | Merck & Co., Inc. | Benzo-Fused Lactams promote release of growth hormone |
US5426185A (en) | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5763437A (en) | 1994-07-29 | 1998-06-09 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0796252A4 (en) | 1994-12-09 | 1998-02-04 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
US5639746A (en) | 1994-12-29 | 1997-06-17 | The Procter & Gamble Company | Hydroxamic acid-containing inhibitors of matrix metalloproteases |
EP0799189A4 (en) | 1994-12-13 | 1999-03-17 | Smithkline Beecham Corp | Bicyclic fibrinogen antagonists |
US5672598A (en) | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5578629A (en) | 1995-03-29 | 1996-11-26 | Merck & Co., Inc. | Benzamide-containing inhibitors of farnesyl-protein transferase |
GB9507799D0 (en) | 1995-04-18 | 1995-05-31 | British Biotech Pharm | Metalloproteinase inhibitors |
US5710171A (en) | 1995-05-24 | 1998-01-20 | Merck & Co., Inc. | Bisphenyl inhibitors of farnesyl-protein transferase |
ES2235171T3 (en) | 1995-05-29 | 2005-07-01 | Pfizer Inc. | DIPEPTIDES THAT PROMOTE THE RELEASE OF THE GROWTH HORMONE. |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0761680A3 (en) | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
WO1997012861A1 (en) * | 1995-10-05 | 1997-04-10 | Chiroscience Limited | Mercaptoamide derivatives and their therapeutic use |
ATE205184T1 (en) | 1995-11-23 | 2001-09-15 | British Biotech Pharm | METALLOPROTEINASE INHIBITORS |
EP0944387A1 (en) | 1996-01-30 | 1999-09-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0891360A4 (en) | 1996-04-03 | 2002-05-15 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000507587A (en) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | Farnesyl protein transferase inhibitor |
US5965578A (en) | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250460A1 (en) | 1996-04-03 | 1997-10-09 | John H. Hutchinson | Inhibitors of farnesyl-protein transferase |
US5885995A (en) | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JP2000513711A (en) | 1996-04-18 | 2000-10-17 | メルク エンド カンパニー インコーポレーテッド | Cancer Treatment |
WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
US5703129A (en) | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
EP0937073A2 (en) | 1996-10-11 | 1999-08-25 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
PL323130A1 (en) | 1996-11-15 | 1998-05-25 | Hoechst Ag | Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such |
EP0951464B1 (en) | 1996-11-22 | 2005-05-11 | Elan Pharmaceuticals, Inc. | N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
CA2272065A1 (en) | 1996-11-22 | 1998-05-28 | Thomas E. Mabry | N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds |
IL129477A0 (en) | 1996-11-22 | 2000-02-29 | Elan Pharm Inc | N-(aryl/heteroaryl)amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
AU5585198A (en) | 1996-11-22 | 1998-06-10 | Athena Pharmaceuticals, Inc. | N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions, and ethods for inhibiting beta-amyloid peptide release and/or its synthesis |
TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
CA2272305A1 (en) * | 1996-12-23 | 1998-07-02 | Elan Pharmaceuticals, Inc. | Cycloalkyl, lactam, lactone and related compounds as .beta.-amyloid peptide release inhibitors |
AU6013998A (en) | 1996-12-30 | 1998-07-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
IL131475A0 (en) | 1997-02-19 | 2001-01-28 | Berlex Lab | N-heterocyclic derivatives as nos inhibitors |
WO1998041510A1 (en) | 1997-03-14 | 1998-09-24 | Shionogi & Co., Ltd. | Novel benzolactam derivatives and medicinal compositions comprising the same |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
JP2001524079A (en) | 1997-04-07 | 2001-11-27 | メルク エンド カンパニー インコーポレーテッド | How to treat cancer |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
DE19726427A1 (en) | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidine-2,4,6-trione derivatives, processes for their preparation and medicaments containing these compounds |
GB9715030D0 (en) | 1997-07-18 | 1997-09-24 | British Biotech Pharm | Metalloproteinase inhibitors |
WO1999007730A1 (en) | 1997-08-11 | 1999-02-18 | Cor Therapeutics, Inc. | SELECTIVE FACTOR Xa INHIBITORS CONTAINING A FUSED AZEPINONE STRUCTURE |
NZ502876A (en) | 1997-08-11 | 2001-11-30 | Cor Therapeutics Inc | Fused bicyclic lactam selective factor Xa inhibitors for treating thrombosis related diseases |
CA2304473A1 (en) | 1997-09-29 | 1999-04-22 | Rajeev S. Bhide | Inhibitors of farnesyl protein transferase |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
JP2003521438A (en) | 1997-12-22 | 2003-07-15 | エラン ファーマシューティカルズ,インコーポレイテッド | Polycyclic α-amino-ε-caprolactam and related compounds |
US6906762B1 (en) | 1998-02-20 | 2005-06-14 | Deep Video Imaging Limited | Multi-layer display and a method for displaying images on such a display |
PA8469501A1 (en) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
WO1999067220A1 (en) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
WO1999066934A1 (en) | 1998-06-22 | 1999-12-29 | Elan Pharmaceuticals, Inc. | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
EP1089980A1 (en) | 1998-06-22 | 2001-04-11 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
JP2002518481A (en) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ,インコーポレイテッド | Compounds for inhibiting the release of β-amyloid peptide and / or its synthesis |
WO2000002903A1 (en) * | 1998-07-10 | 2000-01-20 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
HRP990246A2 (en) * | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
WO2000028331A1 (en) | 1998-11-12 | 2000-05-18 | Du Pont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
BR9917082A (en) | 1998-12-24 | 2001-11-06 | Du Pont Pharm Co | Compounds that inhibit the production of "beta" proteins, a method of treating neurological disorders associated with the production of "beta" -amyloid, pharmaceutical composition and, method of inhibiting y-secretase activity |
EP1261610A2 (en) | 2000-02-17 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production |
-
2001
- 2001-02-16 EP EP01914400A patent/EP1261610A2/en not_active Withdrawn
- 2001-02-16 JP JP2001560210A patent/JP2003523345A/en active Pending
- 2001-02-16 US US09/788,227 patent/US6525044B2/en not_active Expired - Lifetime
- 2001-02-16 CA CA002395862A patent/CA2395862A1/en not_active Abandoned
- 2001-02-16 WO PCT/US2001/005236 patent/WO2001060826A2/en not_active Application Discontinuation
- 2001-02-16 AU AU2001239791A patent/AU2001239791A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001060826A3 (en) | 2002-01-17 |
WO2001060826A2 (en) | 2001-08-23 |
CA2395862A1 (en) | 2001-08-23 |
US6525044B2 (en) | 2003-02-25 |
JP2003523345A (en) | 2003-08-05 |
EP1261610A2 (en) | 2002-12-04 |
US20020055501A1 (en) | 2002-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001239791A1 (en) | Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production | |
AU2001257006A1 (en) | Substituted lactams as inhibitors of abeta protein production | |
AU2002305205A1 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
AU2002213485A1 (en) | Inhibitors of protein kinases | |
AU2002256418A1 (en) | Inhibitors of bace | |
AU7997700A (en) | Amino lactam sulfonamides as inhibitors of abeta protein production | |
AU2002316137A1 (en) | Method of determining protein interaction inhibitors | |
AU2002331311A1 (en) | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv | |
AU2002324468A1 (en) | Rapid improvement of cognition in conditions related to abeta | |
AU2002367147A1 (en) | Beta-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | |
AU2003211093A1 (en) | Inhibitors of rgs proteins | |
AU2001216218A1 (en) | Heterocyclic analgesic compounds and method of use thereof | |
AU2001275530A1 (en) | Inhibitors of c-reactive protein induced inflammation | |
AU2002330453A1 (en) | Crystals of hydroxynorephedrine derivative | |
AU2002306624A1 (en) | Heterocyclic analgesic compounds and methods of use thereof | |
AU2001244692A1 (en) | Novel crystal form of pyrrolidylthiocarbapenem derivative | |
AU2002214286A1 (en) | Method of profiling protein | |
AU2002337913A1 (en) | Glycosulfopeptide inhibitors and methods of use thereof | |
AU2002238103A1 (en) | Use of beta-lactamase inhibitors as neuroprotectants | |
AU1929301A (en) | Methods of use of peptide deformylase inhibitors as novel antibacterial agents | |
AU2003295638A1 (en) | NOVEL INHIBITORS OF Beta-LACTAMASE | |
AU2001249477A1 (en) | Lactams as inhibitors of a-beta protein production | |
AU2002354363A1 (en) | Method of activating protein | |
AU2002305868A1 (en) | Inhibitors of reggamma | |
AU4021700A (en) | Methods of use of beta1-integrin inhibitors |